The use of the humanized monoclonal anti-programmed cell death-1 antibodies pembrolizumab and nivolumab as potent anti-cancer therapies is rapidly increasing. However, since their approval numerous cases of cutaneous reactions have been reported. Cutaneous adverse reactions to these agents have yet to be fully characterized and range from non-specific eruptions to recognizable skin manifestations, which may be localized and vary from mild to life-threatening. This systematic review article provides an overview of the various adverse cutaneous reactions to pembrolizumab and nivolumab therapy and offers suggestions for their management.
|Tidsskrift||Journal of the American Academy of Dermatology|
|Status||Udgivet - 1 nov. 2020|